
PERSONAL INFORMATION

Replace with Pier Luigi Zinzani



University of Bologna Experimental, Diagnostic and Specialty Medicine - DIMES Via Massarenti 9, 40138 Bologna, Italy

6

Sex Male | Date of birth 09/03/1959 | Nationality Italian

Enterprise	University	EPR	
☐ Management Level	☑ Full professor (06/D3 MED/15)	Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator	
☐ Mid-Management Level	☐ Associate Professor	☐ Level III Researcher and Technologist	
☐ Employee / worker level	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	

WORK EXPERIENCE

[Add separate entries for each experience. Start from the most recent.]

Replace with dates (from - to)

2021 - ongoing Head of Lymphomas and Chronic Lymphoproliferative Syndromes Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2018 - ongoing Full Professor of Hematology, University of Bologna, Bologna, Italy 06/D3 MED/15

2016 - ongoing Head of the Center for Phase I studies in Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

1990 - ongoing Resident Physician in Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2002 - 2018 Associate Professor in Hematology, University of Bologna, Bologna, Italy 06/D3 MED/15

٠

EDUCATION AND TRAINING

[Add separate entries for each course. Start from the most recent.]

Replace with dates (from - to)

INSTITUTION AND LOCATION	DEGREE	END DATE	FIELD OF STUDY
	(if applicable)	MM/YYYY	
University of Bologna, Bologna	MD	1984	Medicine and Surgery
University of Bologna, Bologna	PHD	10/1995	Hematology
University of Bologna, Bologna	Specialization	1987	Hematology
Roger Williams cancer Hospital, Providence (USA)	Post doctoral Fellow	1989	Medical Physics
			-

WORK ACTIVITIES

Awards

Karl Musshoff Prize Best Clinical Research Abstract "CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation" ISHL (2016) **Editorial Board, Member**

Editorial activity

2006 - 2009 Leukemia & Lymphoma

2012 - 2016 Clinical Lymphoma Myeloma and Leukemia

Associate Editor

Annals of Oncology 2014 - 2017

Reviewer

Blood

Journal of Clinical Oncology

Haematologica

Leukemia and Lymphoma

European Journal of Haematology

Annals of Oncology

Clinical Lymphoma and Myeloma

Cancer

The Lancet Oncology

Hematological Oncology

Drug

Clinical Cancer Research

Journal of Hematology & Oncology

British Journal of Haematology

Expert Review of Anticancer Therapy

Cancer Letters

Special issue editor for Cancers (2021-ongoing): Special Issue "Non-Hodgkin

Lymphomas"

Invited presentations

Grants

Bando Finalizzata Ministero della Salute Italiano ID project RF-2016-02363730 (2017)

"Design of new personalized therapeutic

approaches for diffuse large B-cell lymphoma",

Patents

none

ADDITIONAL INFORMATION

Publications

All years (1986-2022) source Scopus

total number of publications in peer-review journals: 657 (PubMed)

total Impact Factor (IF) (average IF/paper),

total number of citations 32283

H index 90

Last ten years (2012-2021)

total number of publications in peer-review journals: 332 (PubMed)

Source Web of Science

total number of citations 12335 (16.99 average per item)

H index 54

Replace with relevant publications

https://pubmed.ncbi.nlm.nih.gov/?term=zinzani&sort=date